Abstract
Percutaneous coronary intervention (PCI) is indispensable in the treatment of ischemic heart disease. In the early days of conventional balloon angioplasty, acute coronary occlusion as a result of coronary dissection or vessel recoil was observed immediately after PCI, and initial results were not satisfactory. Moreover, the long-term restenosis rate was 30–40%, and the recurrence of angina was a problem. In order to solve these problems, Sigwart et al. (1) developed a metallic stent, which was used clinically for the first time in 1986. As this pioneering work, the use of stents has become routine in the practice of PCI. Metallic stents are very effective in the prevention of acute coronary occlusion by coronary dissection or recoil of a vessel. Furthermore, the results of large clinical trials, such as STRESS and BENESTENT, suggested that metallic stents are also effective in the prevention of chronic restenosis (2,3). Despite the success that has been achieved with metallic stents, there are also some important limitations. There is a risk of subacute thrombosis (SAT) until endothelial cells cover the surface of the metallic stent. Although the frequency of SAT has been lowered by the use of antiplatelet agents, such as ticlopidine, for at least 1 mo after stent implantation, SAT has not been completely eliminated. Moreover, in-stent restenosis in a complicated coronary lesion poses a significant clinical problem especially with the expanding use of PCI to treat ischemic heart disease. Stents are thought to be required for about 12 mo to prevent lumen narrowing in response to chronic vessel remodeling. As metallic stents remain permanently implanted, there is concern about the deleterious effects of stents on the coronary vessels that may take several years to develop. Furthermore, metallic stents may serve as an obstacle for the treatment of instent restenosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sigwart U, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701–706.
Fischman DL, et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496–501.
Serruys PW, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489–495.
Zidar J, et al. Biodegradable stents. In: Topol EJ, ed. Textbook of interventional cardiology, 2nd ed. WB Saunders, Philadelphia, PA, 1994, pp. 787–802.
Giessen WJ, et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation 1996;94:1690–1697.
Schkenraad JM, et al. Biodegradable hollow fibers for the controlled release of drugs. Biomaterials 1988;9:116–120.
Schakenraad JM, et al. Enzyme activity toward poly (L-lactic acid) implants. J Biomed Mater Res 1990;24:529–545.
Bos RRM, et al. Resorbable poly (L-lactide) plates and screws for the fixation of zygomatic fractures. J Oral Maxillofac Surg 1987;45:751–753.
Suganuma J, et al. Biological response of intramedullary bone to poly-L-lactic acid. J Appl Biomat 1993;4:13–27.
Tamai H, et al. A biodegradable poly-L-lactic acid coronary stent in the porcine coronary artery. J Interven Cardiol 1999;12:443–450.
Tamai H, et al. Initial and 6-month results of biodegradable poly-L-lactic acid coronary stents in humans. Circulation 2000;102:399–404.
Regar E, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation 2002;106:1949–1956.
Liistro F, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002;105:1883–1886.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this chapter
Cite this chapter
Tsuji, T., Tamai, H., Igaki, K. (2007). Biodegradable Stents. In: Duckers, H.J., Nabel, E.G., Serruys, P.W. (eds) Essentials of Restenosis. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-59745-001-0_23
Download citation
DOI: https://doi.org/10.1007/978-1-59745-001-0_23
Publisher Name: Humana Press
Print ISBN: 978-1-58829-491-3
Online ISBN: 978-1-59745-001-0
eBook Packages: MedicineMedicine (R0)